MedPath

OPDUALAG

OPDUALAG

Approved
DIN Number

02541416

Drug Class

Human

Market Date

Feb 12, 2024

Company
HC

bristol-myers squibb canada

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02541416
AIG Number0264981001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L01FY02 NIVOLUMAB AND RELATLIMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (2)

NIVOLUMABActive
Strength: 240 MG / 20 ML
Monograph: NIVOLUMAB
RELATLIMABActive
Strength: 80 MG / 20 ML
Monograph: RELATLIMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.